Comparative analysis of regional outcomes and adverse events after continuous-flow left ventricular assist device implantation: An IMACS analysis

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Standard

Comparative analysis of regional outcomes and adverse events after continuous-flow left ventricular assist device implantation : An IMACS analysis. / Mirza, Kiran K.; Xie, Rongbing; Cowger, Jennifer; Kirklin, James K.; Meyns, Bart; Gustafsson, Finn; Shaw, Steven M.; Goldstein, Daniel J.

I: Journal of Heart and Lung Transplantation, Bind 39, Nr. 9, 2020, s. 904-914.

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Harvard

Mirza, KK, Xie, R, Cowger, J, Kirklin, JK, Meyns, B, Gustafsson, F, Shaw, SM & Goldstein, DJ 2020, 'Comparative analysis of regional outcomes and adverse events after continuous-flow left ventricular assist device implantation: An IMACS analysis', Journal of Heart and Lung Transplantation, bind 39, nr. 9, s. 904-914. https://doi.org/10.1016/j.healun.2020.05.001

APA

Mirza, K. K., Xie, R., Cowger, J., Kirklin, J. K., Meyns, B., Gustafsson, F., Shaw, S. M., & Goldstein, D. J. (2020). Comparative analysis of regional outcomes and adverse events after continuous-flow left ventricular assist device implantation: An IMACS analysis. Journal of Heart and Lung Transplantation, 39(9), 904-914. https://doi.org/10.1016/j.healun.2020.05.001

Vancouver

Mirza KK, Xie R, Cowger J, Kirklin JK, Meyns B, Gustafsson F o.a. Comparative analysis of regional outcomes and adverse events after continuous-flow left ventricular assist device implantation: An IMACS analysis. Journal of Heart and Lung Transplantation. 2020;39(9):904-914. https://doi.org/10.1016/j.healun.2020.05.001

Author

Mirza, Kiran K. ; Xie, Rongbing ; Cowger, Jennifer ; Kirklin, James K. ; Meyns, Bart ; Gustafsson, Finn ; Shaw, Steven M. ; Goldstein, Daniel J. / Comparative analysis of regional outcomes and adverse events after continuous-flow left ventricular assist device implantation : An IMACS analysis. I: Journal of Heart and Lung Transplantation. 2020 ; Bind 39, Nr. 9. s. 904-914.

Bibtex

@article{1ffb3df680504484b0a4d29bec020efa,
title = "Comparative analysis of regional outcomes and adverse events after continuous-flow left ventricular assist device implantation: An IMACS analysis",
abstract = "INTRODUCTION: Regional outcomes after implantation of continuous-flow left ventricular assist devices (LVADs) have not been described. We examined differences in patient selection, survival, and adverse events across 3 geographic regions of the world: the Americas, Asia-Pacific, and Europe. METHODS: Using data from The International Society for Heart and Lung Transplantation Mechanically Assisted Circulatory Support registry, all adult patients implanted with a continuous-flow LVADs were included in this International Society for Heart and Lung Transplantation Mechanically Assisted Circulatory Support analysis (n = 15,560), of whom, 9,988 (64%) received axial-flow devices and 5,572 (36%) received centrifugal-flow devices. RESULTS: There were significant interregional differences in the rate of implantation of patients aged >70 years (Americas: 14%, Asia-Pacific: 1%, Europe: 5%; p < 0.0001), morbidly obese (Americas: 5%, Asia-Pacific: 1%, Europe: 1%; p < 0.0001), male (Americas: 79%, Asia-Pacific: 77%, Europe: 85%; p < 0.0001), and implanted as destination therapy (Americas: 48%, Asia-Pacific: 4%, Europe: 22%; p < 0.0001). The rates of centrifugal pump usage varied by region (Americas: 30%, Asia-Pacific: 34%, Eu: 74%; p < 0.0001). Survival rates varied by region and the type of pump flow, with survival at 12 and 48 months (axial flow vs centrifugal flow) being 82% vs 82% and 52% vs 53 in Americas; 92% vs 86% and 83% vs 74% in Asia-Pacific; and 80% vs 75% and 69% vs 53% in Europe, respectively (regional survival p < 0.0001). CONCLUSION: There are marked global differences in LVAD recipient characteristics, device utilization, and post-operative care. These heterogeneities along with differences in patient management and transplantation rates may impact long-term survival. Regional differences in adverse event incidence warrant further investigation.",
keywords = "Americas, Asia-Pacific, continuous flow, Europe, left ventricular assist device, outcome",
author = "Mirza, {Kiran K.} and Rongbing Xie and Jennifer Cowger and Kirklin, {James K.} and Bart Meyns and Finn Gustafsson and Shaw, {Steven M.} and Goldstein, {Daniel J.}",
year = "2020",
doi = "10.1016/j.healun.2020.05.001",
language = "English",
volume = "39",
pages = "904--914",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier",
number = "9",

}

RIS

TY - JOUR

T1 - Comparative analysis of regional outcomes and adverse events after continuous-flow left ventricular assist device implantation

T2 - An IMACS analysis

AU - Mirza, Kiran K.

AU - Xie, Rongbing

AU - Cowger, Jennifer

AU - Kirklin, James K.

AU - Meyns, Bart

AU - Gustafsson, Finn

AU - Shaw, Steven M.

AU - Goldstein, Daniel J.

PY - 2020

Y1 - 2020

N2 - INTRODUCTION: Regional outcomes after implantation of continuous-flow left ventricular assist devices (LVADs) have not been described. We examined differences in patient selection, survival, and adverse events across 3 geographic regions of the world: the Americas, Asia-Pacific, and Europe. METHODS: Using data from The International Society for Heart and Lung Transplantation Mechanically Assisted Circulatory Support registry, all adult patients implanted with a continuous-flow LVADs were included in this International Society for Heart and Lung Transplantation Mechanically Assisted Circulatory Support analysis (n = 15,560), of whom, 9,988 (64%) received axial-flow devices and 5,572 (36%) received centrifugal-flow devices. RESULTS: There were significant interregional differences in the rate of implantation of patients aged >70 years (Americas: 14%, Asia-Pacific: 1%, Europe: 5%; p < 0.0001), morbidly obese (Americas: 5%, Asia-Pacific: 1%, Europe: 1%; p < 0.0001), male (Americas: 79%, Asia-Pacific: 77%, Europe: 85%; p < 0.0001), and implanted as destination therapy (Americas: 48%, Asia-Pacific: 4%, Europe: 22%; p < 0.0001). The rates of centrifugal pump usage varied by region (Americas: 30%, Asia-Pacific: 34%, Eu: 74%; p < 0.0001). Survival rates varied by region and the type of pump flow, with survival at 12 and 48 months (axial flow vs centrifugal flow) being 82% vs 82% and 52% vs 53 in Americas; 92% vs 86% and 83% vs 74% in Asia-Pacific; and 80% vs 75% and 69% vs 53% in Europe, respectively (regional survival p < 0.0001). CONCLUSION: There are marked global differences in LVAD recipient characteristics, device utilization, and post-operative care. These heterogeneities along with differences in patient management and transplantation rates may impact long-term survival. Regional differences in adverse event incidence warrant further investigation.

AB - INTRODUCTION: Regional outcomes after implantation of continuous-flow left ventricular assist devices (LVADs) have not been described. We examined differences in patient selection, survival, and adverse events across 3 geographic regions of the world: the Americas, Asia-Pacific, and Europe. METHODS: Using data from The International Society for Heart and Lung Transplantation Mechanically Assisted Circulatory Support registry, all adult patients implanted with a continuous-flow LVADs were included in this International Society for Heart and Lung Transplantation Mechanically Assisted Circulatory Support analysis (n = 15,560), of whom, 9,988 (64%) received axial-flow devices and 5,572 (36%) received centrifugal-flow devices. RESULTS: There were significant interregional differences in the rate of implantation of patients aged >70 years (Americas: 14%, Asia-Pacific: 1%, Europe: 5%; p < 0.0001), morbidly obese (Americas: 5%, Asia-Pacific: 1%, Europe: 1%; p < 0.0001), male (Americas: 79%, Asia-Pacific: 77%, Europe: 85%; p < 0.0001), and implanted as destination therapy (Americas: 48%, Asia-Pacific: 4%, Europe: 22%; p < 0.0001). The rates of centrifugal pump usage varied by region (Americas: 30%, Asia-Pacific: 34%, Eu: 74%; p < 0.0001). Survival rates varied by region and the type of pump flow, with survival at 12 and 48 months (axial flow vs centrifugal flow) being 82% vs 82% and 52% vs 53 in Americas; 92% vs 86% and 83% vs 74% in Asia-Pacific; and 80% vs 75% and 69% vs 53% in Europe, respectively (regional survival p < 0.0001). CONCLUSION: There are marked global differences in LVAD recipient characteristics, device utilization, and post-operative care. These heterogeneities along with differences in patient management and transplantation rates may impact long-term survival. Regional differences in adverse event incidence warrant further investigation.

KW - Americas

KW - Asia-Pacific

KW - continuous flow

KW - Europe

KW - left ventricular assist device

KW - outcome

U2 - 10.1016/j.healun.2020.05.001

DO - 10.1016/j.healun.2020.05.001

M3 - Journal article

C2 - 32487472

AN - SCOPUS:85085614165

VL - 39

SP - 904

EP - 914

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 9

ER -

ID: 250548413